Tiziana Life Sciences 6-K Report: Positive Updates on Multiple Sclerosis Treatment

Here are the key insights extracted from the financial report of Tiziana Life Sciences LTD filed as Form 6-K:

1. Type of Filing: This is a Form 6-K report, which is used by foreign private issuers to provide information to the SEC.
2. Date of Report: The report is dated February 18, 2025.
3. Company Information:

• Name: Tiziana Life Sciences LTD
• Commission File Number: 001-38723
• Address: 9th Floor, 107 Cheapside, London, EC2V 6DN

4. Key Announcement:

• The company announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access (ISPPEA) program aimed at patients with non-active secondary progressive multiple sclerosis (na-SPMS).
• As of the date of the report, a total of 14 patients have been enrolled in the expanded access program.
• Notably, the first 10 patients in the program have shown either improvement or stability in their condition within six months of starting treatment.

5. Exhibit Provided: The announcement is included as Exhibit 99.1, which is a press release dated February 18, 2025.
6. Liability Disclaimer: The information in Exhibit 99.1 is furnished and shall not be considered "filed" under the Securities Exchange Act of 1934, thus limiting the liabilities associated with it.
7. Signatory Information:

• Name of Signatory: Keeren Shah
• Title: Chief Financial Officer
• Signature Date: February 18, 2025

This report highlights Tiziana Life Sciences’ ongoing commitment to their research and development efforts in treating multiple sclerosis, indicating positive early results from their expanded access program.